Zeglis‘ Lab at Hunter College created a methodology that facilitates the dual labeling of an antibody with both a toxin and a radionuclide (89Zr-Trastuzumab-MMAE immunoconjugate) for both breast cancer therapy and clear PET imaging.
Read more: http://bit.ly/2Hl37wM
